JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31

Jazz Pharmaceuticals plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$208.43−1.80 (-0.86%)

Close on Oct 19, 2026

Market cap: $14.47B
P/E (TTM): 14.3
Dividend yield: –

Jazz Pharmaceuticals plc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	4,268	4,069	3,834	3,659	3,094	2,364	2,162	1,891	1,619	1,488	1,325	1,173	872	586	272	174	128
Research & Development	783	884	850	590	506	335	300	227	198	162	135	85	42	20	14	26	37
Selling, General & Admin	1,809	1,385	1,343	1,417	1,452	854	737	684	544	503	449	406	304	224	109	69	59
Advertising Expenses	106	107	92	109	162	100	65	37	37	30	28	26	1.00	0.70	1.00	1.60	0.40
Operating Expenses	–	–	–	–	–	–	–	1,276	1,090	896	817	977	532	388	144	116	113
Total Costs & Expenses	4,698	3,352	3,256	3,725	2,924	1,985	1,629	1,276	1,090	–	–	–	–	–	–	–	–
Operating Income	-430	717	579	-66	170	378	532	615	529	592	508	196	340	198	128	58	16
Interest Expense	–	–	33	33	90	88	63	57	38	28	27	–	–	–	1.68	13	23
Interest & Investment Income	86	106	65	12	1.80	11	21	17	4.10	–	–	–	–	–	0.08	0.00	0.03
Income from Equity Investments	-0.73	-1.66	-3.01	-9.92	-0.71	-2.96	-4.09	-2.20	-1.01	-0.38	0	0	–	–	–	–	–
Other Non-Operating Income	–	–	–	–	–	–	–	–	–	–	1.45	8.68	-1.70	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	1.64	1.94	1.46	–	–	–	–
Asset Impairment Charges	–	0	0	134	0	136	0	43	0	0	32	39	0	–	–	–	–
Gain (Loss) on Sale of Assets	–	0	0	-38	0	–	-0.02	-0.66	-0.47	-0.05	-0.17	-0.02	-0.05	-0.16	-0.03	-0.28	-0.01
Pretax Income	-628	470	298	-373	-113	275	454	529	441	532	436	152	308	177	125	33	–
Income Tax Expense	-272	-91	-120	-159	216	34	-73	80	-48	135	106	94	92	-84	0	0	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	57	216	261	125	33	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	0	0	27	0	0	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	447	488	397	330	57	216	289	–	–	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	0	0	0.00	-1.06	0	0	–	–	–
Net Income	-356	560	415	-224	-330	239	523	447	488	397	330	58	216	289	125	33	-6.84
Net Income to Common	-356	571	440	-224	-330	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-5.84	9.06	6.55	-3.58	-5.52	4.28	9.22	7.45	8.13	6.56	5.38	0.98	3.71	5.09	3.01	0.90	-0.23
EPS (Diluted)(per share)	-5.84	8.65	6.10	-3.58	-5.52	4.22	9.09	7.30	7.96	6.41	5.23	0.93	3.51	4.79	2.67	0.83	-0.23
Shares Outstanding (Basic, Weighted)(shares)	61	62	63	63	60	56	57	60	60	61	61	60	58	57	41	36	30
Shares Outstanding (Diluted, Weighted)(shares)	61	66	72	63	60	57	58	61	61	62	63	63	62	60	47	39	30
EBITDA	-389	749	609	-35	197	397	548	630	542	603	518	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 19.5%
Net margin: 20.4%
Return on equity, FY2025: -8.5%

Financial strength

Current ratio: 1.78
Debt to equity: 0.91
Debt to assets: 39.3%
Cash to current liabilities: 72.6%

Valuation

P/E ratio: 14.3
Price to sales: 3.14
Price to book: 3.01
Dividend yield: –